Stock, pipeline and biotech catalyst intelligence
Clinical portfolio
| Asset | Indication | Stage | Milestone | Signals ? |
|---|---|---|---|---|
| Belzupacap Sarotalocan (Bel-sar) | Early-Stage Choroidal Melanoma | Phase 3 | Dec 31, 2027 | Mgmt interest |
| Belzupacap Sarotalocan (AU-011) (Virus-Like Conjugate) | Metastases To The Choroid | Phase 2 | Dec 31, 2026 | — |
| Belzupacap Sarotalocan (Bel-sar) (AU-011) | Non-Muscle-Invasive Bladder Cancer (NMIBC) | Phase 1/2 | TBA | — |
Upcoming milestones
Company profile
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. It focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer. The company was incorporated in 2009 and is headquartered in Boston, Massachusetts.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.
Non-Muscle-Invasive Bladder Cancer (NMIBC)
UpdateMetastases To The Choroid
Data readout